HI HB562

Prohibits 340B covered entities in Hawaii from entering contracts with drug manufacturers or wholesale distributors that restrict or prohibit acquiring 340B drugs through contract pharmacies, effective June 30, 2025

Voids any contract provisions for drugs sold based on the maximum allowable cost payment model that were in effect on or before June 30, 2025

Authorizes the attorney general to bring civil actions on behalf of individuals whose rights under this law have been violated

Protects the federal 340B drug pricing program, which provides medication discounts to nonprofit hospitals, safety net providers, rural hospitals, community health centers, and Native Hawaiian health centers serving low-income and uninsured populations

Addresses drug manufacturer practices since 2020 that have limited 340B entities' ability to use contract pharmacies, which is particularly critical in Hawaii's rural and geographically isolated communities